Abstract : Rituximab RTX is an anti-CD20 human-mouse chimeric monoclonal antibody that exhibits antibody-dependent, cell-mediated cytotoxicity and complementdependent cytotoxicity, resulting in an antitumor effect with immune cells or complement. RTX is approved for the treatment of many diseases including B cell lymphoma and rheumatoid arthritis. We examined whether combined RTX and gamma interferon IFN therapy provides a higher antitumor effect than RTX single therapy using B-cell lymphoma cells. In addition, we investigated the mechanisms underlying the antitumor effect. We treated tumor-derived cell lines with RTX alone, IFN alone, or a combination of RTX and IFN RTX-IFN . Untreated cells served as controls. We experimentally examined in vitro cell proliferation, conducted apoptosis and cell cycle assays, performed Western blotting to identify changes in the levels of proteins related to the cell cycle, and investigated tumor growth in a mouse xenograft experiment. Cell proliferation experiments indicated that RTX or IFN alone did not signi cantly suppress cell growth compared with the control, whereas treatment with RTX-IFN signi cantly suppressed cell proliferation. In vivo mouse experiments also showed that the administration of RTX-IFN signi cantly suppressed tumor growth compared to the single therapies. Some tumors in mice treated with RTX-IFN were completely resolved. The cell cycle assays revealed a signi cantly increased rate of cells in the G0/G1 phase following treatment with RTX-IFN compared with the other groups, and the levels of p27 kip1 increased and the levels of cyclin E and Cdk 2 decreased in cells treated with RTX-IFN . Our ndings suggested that RTX-IFN combined therapy directly affects cells by arresting the cell cycle at the G1/S checkpoint and had a synergistic antitumor effect compared to RTX single treatment of B-cell lymphomas. This combined therapy may change the mortality rate for B-cell lymphomas.
Introduction
Rituximab RTX is an anti-CD20 human-mouse chimeric monoclonal antibody that shows antibody-dependent cell-mediated cytotoxicity ADCC and complement-dependent cytotoxicity CDC . It is also the first monoclonal antibody to be used for clinical cancer therapy. RTX is combined with several chemotherapies for treating B cell lymphoma and is used alone to treat autoimmune diseases such as rheumatism. Clinical trials have already provided evidence on the safety of RTX [1] [2] [3] [4] .
Historically, it was anticipated that gamma interferon IFN would exhibit antitumor effects ; however, clinical trials in the 1980s on its efficacy as a cancer therapy showed no antitumor effects, thus IFN was not pursued as a cancer therapy 5 . IFN is a type interferon secreted as a cytokine by natural killer cells, dendritic cells, and CD8 T cells [6] [7] [8] . Several reports indicate that selected molecular target drugs require type and interferon for efficacy 9 .
We previously reported that combined anti-HER2 antibody and IFN therapy showed a higher antitumor effect than anti-HER2 antibody single therapy 10 . Her2 is regarded as an oncogene because overexpression of HER2 causes cells to become malignant. In contrast, CD20 is not an oncogene. In addition, cancers that overexpress HER2 form solid tumors, whereas lymphomas are humoral tumors.
In this study, we examined whether combined RTX and IFN therapy RTX-IFN provides a higher antitumor effect than RTX single therapy using B-cell lymphoma cells. We also investigated the mechanisms related to any synergistic antitumor effects observed.
Materials and methods

Cell lines and culture conditions
The Raji and RAMOS cell lines are Burkitt s lymphoma cells that originated from B lymphocytes. Both cell lines were obtained from the American Type Culture Collection ATCC, Manassas, VA and were cultivated in RPMI-1640 growth medium containing L-glutamine and 10 fetal bovine serum Biosera, Kansas City, MO .
Drugs
RTX was obtained from Chugai Chugai Pharmaceutical Co., Ltd., Tokyo, Japan and human IFN was obtained from PROSPEC PROSPEC Protein Specialists, Rohovot, Israel . We diluted the RTX with phosphate-buffered saline PBS to a final concentration of 1 mg/ml and IFN to a final concentration of 1 10 5 IU/ml. For all RTX and IFN combined treatment experiments, IFN was added 30 minutes after the addition of RTX.
Cell growth assay
We used four groups of Raji and RAMOS cells : control group, RTX group, IFN group, and RTX-IFN group. Cells 1 10 5 of Raji or 5 10 5 of RAMOS were seeded onto 6-well plates four groups, and cultured in RPMI-1640 containing L-glutamine and 10 fetal bovine serum. Drug treatment was initiated 8 hours after the cell passage, and then the cells were cultured for a further 24, 48, or 72 hours. The cells were counted at each time using an automated cell counter Bio-Rad Laboratories, Inc., Hercules, CA and a cell growth curve was constructed. No drugs were added to the control group, the RTX group was treated with 10 µg/ml of RTX, the IFN group was treated with 100 IU/ml of IFN , and the RTX-IFN group was treated with 10 µg/ml of RTX and 100 IU/ml of IFN .
Cell apoptosis assay
Cells 5 10 5 were seeded onto 6-well plates, and then treated for 48 hours with RTX, IFN , or RTX-IFN ; the control group was not treated with drugs. Following treatment, the cell number was adjusted to between 1 10 6 and 1 10 7 /100 µl in culture medium, and then stained using a Mouse Annexin V and Dead Cell Assay Kit Merck Group, Darmstadt, Germany . The cells were analyzed using a flow cytometer Merck Group .
Cell cycle analysis
Cells 1 10 5 were seeded onto 6-well plates, then 2 mM hydroxyurea was added to each well to synchronize the cell cycle phase for 12 hours. The cells were then treated for 8 hours with RTX, IFN , or RTX-IFN , or left untreated as control. The cells were then washed with PBS, collected by pipetting, and fixed with 75 cold ethanol for 4 hours at 20 . The cells were incubated and the cell cycle phase was determined using a flow cytometer and a Cell Cycle Assay Kit Merck Group .
Lysate preparation and Western blotting
Cells 1 10 6 were seeded onto 6-well plates and cultured with each drug or the drug combination for 48 hours, and then lysed in RIPA buffer Wako Pure Chemical Industries, Ltd., Osaka, Japan containing a protease inhibitor cocktail Sigma-Aldrich, St. Louis, MO , before analysis by Western blotting.
In Cell Signaling Technology, Danvers, MA , a mouse antibody against cyclin E Santa Cruz Biotechnology, Dallas, TX , or a mouse antibody against Cdk 2 Santa Cruz Biotechnology . The membranes were then washed three times in PBS containing 0.1 Tween 20 and incubated for 1 hour with either a goat anti-rabbit IgG antibody conjugated with horseradish peroxidase SeraCare Life Sciences, Milford, MA as a secondary antibody for the p27 kip1 primary antibody or a goat anti-mouse IgG antibody conjugated with horseradish peroxidase Santa Cruz Biotechnology, Dallas, TX as a secondary antibody for the cyclin E and Cdk 2 primary antibodies. Protein bands were measured using a LI-COR 3600 computerized digital imaging system LI-COR, Inc., Lincoln, NE .
Mouse in vivo experiment
Eight-week-old female C.B-17 SCID mice, which have a severe combined immunodeficiency affecting both B and T lymphocytes, were purchased CHARLES RIVER LABORATORIES JAPAN, Inc., Yokohama, Japan and bred for one week to allow adjustment prior to the experiment. Raji cells 1 10 7 were injected subcutaneously into both sides of the back of each mouse.
We divided the mice into four groups so that the average tumor size in each group was similar and initiated drug treatment 14 days after cell inoculation. The control group was treated with 100 µl PBS, the RTX group with 100 mg/100 µl RTX in PBS, the IFN group with 10,000 IU/100 µl IFN in PBS, and the RTX-IFN combined therapy group with both drugs. The drugs were delivered by intraperitoneal injection. For the combined therapy group, IFN was injected 30 minutes after the RTX injection. The experiment was performed for four weeks. Tumors were measured three times a week using a digital caliper and tumor size was calculated as length width height. The drugs were administered three times a week.
Statistical analysis
Statistical analysis was carried out using YSAT 2013 Igakutosho-shuppan Ltd., Toda, Japan . Differences in mean values were statistically analyzed using non-repeated measures ANOVA, followed by Dunnett s test or the Student-Newman-Keuls test. Tumor volume differences between the RTX and RTX-IFN groups were statistically analyzed using unpaired Student s t-test. The threshold for significance was P 0.05 in all statistical analyses.
Results
Cell proliferation
Raji cells RTX-IFN treatment was more effective at suppressing cell proliferation than RTX treatment on Day 2 and Day 3 after drug treatment. On Day 3, proliferation of the RTX-IFN group cells was 60 of the control group, whereas that of the RTX group was 89 of the control group. Cell counts were significantly decreased in the RTX-IFN treatment group compared to the control group, whereas the RTX and IFN groups showed no significant difference compared to the control group. Indeed, the IFN group showed an increased number of Raji cells Fig. 1a .
Ramos cells The same in vitro experiment using RAMOS cells showed that cell proliferation in the RTX-IFN group was 69 of the control group on Day 3, whereas proliferation of the RTX group was 88 of the control group on Day 3. Also on Day 3, the RTX-IFN group showed significant suppression of cell proliferation compared to the control group, whereas treatment with RTX or IFN alone showed no significant difference compared to the control group Fig. 1b .
Cell apoptosis assay
The percentage of apoptotic cells was not significantly different among the four groups, as shown by flow cytometry Fig. 2 .
Cell cycle assay
We subjected Raji cells to a cell cycle assay to investigate why RTX-IFN treatment suppressed cell proliferation without affecting apoptosis.
The percentage of cells in G0/G1 phase was significantly increased in the RTX-IFN group compared with that in the other three groups Fig. 3 , and there was no significant difference in the percentage of cells in S phase and G2/M phase among the four groups data not shown .
Cells treated with RTX or IFN alone showed no significant difference in the percentage of cells in G0/1 phase compared with the control group, and RTX induced G1/S checkpoint cell arrest only when combined with IFN .
Western blotting
We then investigated the cell arrest findings at the G1/S checkpoint in cells treated with RTX-IFN using Western blot analysis. The expression level of p27 kip1 protein was increased and were seeded in 6-well plates with 3 ml of medium and divided into four groups : control, RTX 10 µg/ml , IFN 100 IU/ml , and RTX-IFN 10 µg/ml 100 IU/ml ; IFN was added 30 minutes after the additions of RTX . Drug treatment was started 8 hours after passage and the cells were counted at 24, 48, and 72 hours. The curves show the mean standard deviation of the number of cells from three independent culture experiments. Treatment with RTX-IFN significantly suppressed cell proliferation compared with the control, whereas treatment with RTX or IFN alone resulted in no significant difference in cell proliferation compared to the control on Day 3 Dunnett s test, P 0.01 vs. control, N 3 .
that of both Cdk 2 and Cyclin E was decreased in the RTX-IFN group in the Raji cell line compared to the other groups Fig. 4 .
Antitumor effect in vivo
We conducted in vivo experiments in mice to investigate the antitumor effect of RTX-IFN administration and the effect of ADCC and CDC. were seeded in 6-well plates. The cells were divided into four groups : control, RTX 10 µg/ml , IFN 100 IU/ml , and RTX-IFN 10 µg/ml 100 IU/ml . The figure shows the mean standard deviation of the ratio of apoptotic Raji cells from three independent culture experiments. The data excluded debris. There was no significant difference among the four groups in the ratio between apoptotic and living cells N 3 . , cyclin E, and Cdk 2, which are related to G1/S checkpoint arrest, using Western blotting. Raji cells 1 10 6 were seeded in 6-well plates and cultured with each drug for 48 hours. The expression level of p27 kip1 increased and that of cyclin E and Cdk 2 decreased in the RTX-IFN group compared to the other groups. 
Discussion
Tumor-derived cells were treated with RTX alone, IFN alone, or RTX-IFN . Untreated cells served as controls. We experimentally examined in vitro cell proliferation, conducted apoptosis and cell cycle assays, performed Western blotting to identify changes in the levels of proteins related to the cell cycle, and investigated tumor growth in a mice xenograft experiment.
In cell proliferation experiments, treatment with RTX or IFN alone induced no significant suppression compared with the control, whereas treatment with RTX-IFN significantly suppressed cell proliferation. In the in vivo mouse experiments, the administration of RTX-IFN significantly suppressed tumor growth compared with the single therapies. Cell cycle assays showed that the ratio of cells in G0/G1 phase significantly increased following exposure to RTX-IFN compared with the other groups. Furthermore, RTX-IFN treatment increased the level of p27 kip1 protein and decreased the levels of Cyclin E and Cdk 2 protein in the single treatment groups.
Treatment of lymphomas with RTX
RTX is an anti-human CD20 antibody used to treat various diseases because normal B cells express CD20 on the surface from the Pro B cell phase. B-cell non-Hodgkin lymphoma is treated by administering RTX combined with chemotherapeutic agents such as cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone CHOP is used as a first-line treatment. RTX can enhance the antitumor effect of chemotherapeutics and decrease the required drug dose and associated side effects. Therefore, RTX may allow the safer use of chemotherapeutics by patients unable to tolerate full-dose chemotherapy.
A new mechanism for an antitumor effect : arresting the cell cycle IFN alone showed no antitumor effect in either in vitro or in vivo experiments, whereas treatment with RTX-IFN showed a higher antitumor effect than RTX alone. This is consistent with a previous study showing that trastuzumab and IFN combined therapy extended tumorfree survival 10 . Indeed, some tumors in the present study were completely resolved following treatment with RTX-IFN . RTX-IFN combined therapy may therefore strongly enhance the antitumor effects of clinical chemotherapeutics, allowing their dose to be reduced. Therefore, treatment with RTX-IFN might extend the survival rate of patients with B cell lymphoma. RTX is thought to exhibit ADCC and CDC, resulting in an antitumor effect ; however, ADCC and CDC require secondary signals. In the presented in vitro experiments, the medium lacked effector cells or active complement and RTX single therapy did not significantly reduce cell numbers compared with the control. In contrast, treatment with RTX-IFN reduced cell numbers in the absence of effector cells or active complement in the presented in vitro experiments.
Trastuzumab can induce antibody internalization within 24 hours after binding to erbB2 receptors on the cell membrane, resulting in apoptosis 11 . Trastuzumab also can induce signal transduction and phenotypic changes in cells. In contrast, RTX does not induce antibody-internalization and thus cannot induce cell apoptosis 12 . We observed no significant differences in apoptosis among the four groups in the current study, thereby demonstrating that treatment with RTX-IFN has an antitumor effect without causing apoptosis and necrosis.
Suppressing the malignant potential of cancer by arresting the cell cycle
There are several reports that treatment of HER2-positive breast cancer with trastuzumab can change the malignant phenotype [13] [14] [15] . The cell cycle assay used in this study showed a significant increase in the number of cells in the G0/G1 phase following treatment with RTX-IFN compared with the other three groups. We therefore investigated several proteins related to the G1/S checkpoint using Western blotting and found that p27 kip1 increased and cyclin E and Cdk 2 decreased in cells treated with RTX-IFN . These changes might reflect cell cycle arrest at the G1/S checkpoint and suggest that RTX-IFN can change the malignant phenotype to arrest the cell cycle. Cells undergoing abnormal cell proliferation tend to accumulate genetic mutations [16] [17] [18] [19] , which can in turn increase the malignant potential of cancers and remarkably increase patient mortality, because the mutations promote adaptation to the microenvironment, metastatic ability, and treatment resistance [20] [21] [22] . RTX-IFN can affect the G1/S checkpoint and arrest the cell cycle leading to suppression of mutagenesis, thereby preventing the accumulation of gene mutation and subsequent enhancement of carcinogenesis.
RTX treatment for autoimmune diseases
RTX reduces the number of plasma cells with ADCC and CDC, and is used for the treatment of many diseases such as idiopathic thrombocytopenic purpura, rheumatoid arthritis, and systemic lupus erythematosus 23 . In this study, we demonstrated that RTX-IFN reduced the number of B-cells, suggesting that treatment with RTX-IFN could be more effective for the treatment of these diseases compared to RTX alone.
Limitations
We did not investigate the antitumor effect of RTX-IFN combined with chemotherapies. We also did not investigate markers related to the epithelial-mesenchymal transition, such as Snail, Slug, and TWIST, or the relationship between cell cycle arrest and epithelial-mesenchymal transition by measuring TGF-.
Conclusions
RTX-IFN combined therapy may induce a synergistic antitumor effect superior to RTX single therapy. RTX-IFN acts via a new antitumor mechanism, affecting cancer cells by arresting the cell cycle. Our study suggests that RTX-IFN treatment may enhance clinical chemotherapies, reduce the dose of chemotherapeutics, and extend tumor-free survival. RTX-IFN is expected to arrest the cell cycle and therefore prevent increase in malignancy.
